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Background: Breast cancer (BC) is among the most common oncologic pathology in economically developed countries where 
it afflicts nearly 10% of women. Polymorphism of CYP 2D6 gene is shown to be associated with increased risk of development 
of a number of pathologies, in particular cancer. Aim: The work was directed on evaluation of the role of polymorphism G1934A 
(allele *4) of CYP 2D6 gene in elevated risk of BC development in Ukrainian women. Materials and Methods: In the study there 
were enrolled 85 patients (group І) with histologically verified BC diagnosis of stages I and ІІ. Clinical-genealogic study has been 
performed by the method of patient survey and following analysis of genealogy. Earlier obtained data on the frequency of genotypes 
and alleles of CYP 2D6 gene in 637 Ukrainian people have been used as a control. For determination of allele variant *4 (G1934A) 
of CYP 2D6 gene the method of PCR-RFLP has been used. Results: An increased risk of BC development in hereditary tainted 
patients with genotype *4*4 of CYP 2D6 gene compared to the control group has been revealed. The frequency of *1*4 (IM) 
genotype has been found to be increased in the group of women with a family history of cancer (41.79%). Significant difference 
between the frequency of *1*1 (ЕМ) and *1*4 (ІМ) genotypes in females with PR-positive and PR-negative tumors in the group 
of hereditary tainted patients has been registered. Conclusion: In conclusion, our study has revealed an increased risk of BC de-
velopment in hereditary tainted patients compared to control group with genotype *4*4 (РМ).
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Breast cancer (BC) is among the most common 
oncologic pathology in economically developed 
countries where it afflicts nearly 10% of women. The 
main causes of increased BC frequency account ag-
ing of population, prolonged influence of estrogens, 
and genome instability [1]. The CYP 2D6 mutant 
genotype has been reported to inﬂuence susceptibil-
ity to a number of cancers, such as lung, neck, liver 
cancer, melanoma and other types malignant diseases 
[14]. Numerous studies are devoted to the search 
of associations between the risk of BC development 
and individual patterns of the system of enzymes in-
volved in metabolism of carcinogenes. Of doubtless 
interest are the studies directed on genetic polymor-
phism of enzymes that participate on metabolism 
of hormones, because the hereditary nature of hor-
monal signature of each individual and a prominent 
role of hyperestrogenemia in BC development have 
been demonstrated [2].
Among enzymes involved in metabolism of estro-
gens one could mention debrisoquine-4-hydroxylase 
(CYP 2D6) — an ensyme of phase І xenobiotic detoxi-
fication. It has been shown that CYP 2D6 takes part 
in the metabolism of 25% of all medicinal agents in-
cluding cytotoxic preparations (tamoxyphen) used for 
BC therapy [5]. The enzymes activity of CYP 2D6 was 
only found in the liver, intestines and brain. Disease oc-
currence seems to be associated with the distribution 
of the cytochromes activity within different organs [15].
By the level of CYP 2D6 activity one could select 
poor metabolizers (РМ), intermediate metabolizers 
(IM), extensive metabolizers (EM), and ultrarapid 
metabolizers (UM) [6].
CYP 2D6 enzyme demonstrates a wide spectrum 
of inter-individual variations in the rate of metabolism, 
and its activity levels differ in various population groups 
[7]. In the majority of cases, CYP 2D6 is capable to me-
tabolise its substrates quickly. This level of activity 
of the enzyme (EM) is associated with genotype that 
is responding to wild type homozygote — genotype 
*1*1.
CYP 2D6 gene is localized on chromosome 
22q13.1. (ОMIM *124030). In white European popula-
tion in CYP 2D6 gene the most often found substitution 
is G1934A (allele *4) on the line between intron 3 and 
exon 4, the presence of which leads to incorrect mRNA 
splicing resulting in a shift of reading frame, termina-
tion of translation, and generation of defective protein 
product lacking enzymatic activity (Fig. 1) [8].
G to А substitution is identified as a primary defect 
in CYP 2D6 locus, and by various estimations it is pres-
ent in 80–90% of mutant alleles of poor metabolizers 
[9]. It has been shown that allele *4 is associated 
with decreased CYP 2D6 activity [8]. In nearly 5–10% 
of white European population there have been de-
tected mutations in both alleles of CYP 2D6 gene — 
genotype *4*4 related to РМ.
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Fig. 1. G1934A polymorphism in intron 3 of CYP2D6 gene
The carriers of only one allele *4 (heterozygous 
state) are intermediate metabolizers (IM) of CYP 
2D6 substrates — genotype *1*4.
CYP2D6 participates in metabolic activation 
of procarcinogens, so, in patients with EM phenotype 
compared to other groups with lower enzyme activ-
ity, larger amounts of reaction-active compounds 
may be formed what in turn may lead to malignant 
transformation. However, the results of compara-
tive evaluation of the role of CYP 2D6 allele variants 
in cancer development are conflicting [10, 11]. Apart 
from this, polymorphism of CYP 2D6 gene is thought 
to be related to the increased risk of the develop-
ment of a number of diseases, including some types 
of cancer [3, 4].
In Ukraine, only general frequency of alleles and 
genotypes by polymorphic variant G1934A (allele 
*4) of CYP 2D6 gene has been studied [12], but the 
relation between the frequency of genotypes of this 
polymorphic variant with increased risk of BC develop-
ment has not been studied yet.
The aim of our study was to evaluate the role of ge-
netic polymorphism G1934A (allele *4) of CYP 2D6 gene 
in elevated risk of breast cancer development in Ukrai-
nian women.
MATERIALS AND METHODS
The study protocol was approved by the Committee 
for the Ethical Issues of P.L. Shupik National Medical 
Academy of Post-Graduate Education. All patients 
have signed an informed consent.
In the study there were enrolled 85 female ethnic 
Ukrainian patients (group І) from 18 to 80 years old 
(average age — 45.25±13.26 years) with histologically 
verified diagnosis of lobular and/or ductal BC of stages 
I and ІІ, who received treatment in Kyiv Municipal On-
cological clinics. All patients were involved in clinico-
genealogic study by the method of survey where all 
information has been fixed in a specially developed 
file with the following analysis of genealogy. Accord-
ing to the results of such clinico-genealogic study all 
patients were randomized in two subgroups: group 
Іa — 67 patients who have 2 or more BC cases among 
the relatives of І–ІІ degree of kin (hereditary tainted 
patients); group Іb — 18 patients who have no rela-
tives with cancer (hereditary untainted patients). The 
control group was represented with Ukrainian people 
(n=637, average age 50.73±19.3 years). During the 
study of population frequency of CYP 2D6*4 genotypes 
in females and males and individuals from different 
age groups we have registered no significant differ-
ences, that’s why we have united them into one group 
(control group).
Genomic DNA was extracted from the peripheral 
leukocytes using standard procedures. For determi-
nation of allele variant *4 (G1934A) of CYP 2D6 gene 
the method of PCR-RFLP (polymerase chain reac-
tion — restriction fragment length polymorphism) 
has been used. PCR-RFLP was carried out by the 
method of Brown et al. [13]. Amplification reaction 
was performed in thermocycler Applied Biosystems 
2700. DNA was denatured for 3 min at +94 °С, with 
the following 30 cycles at +94 °С for 40 s, at +60 °С for 
40 s, and at +72 °С for 40 s.
The products of amplification (421 b.p. in length) 
underwent restriction with restriction endonuclease 
BstNI (MvaI) (Fermentаs, Lietuva), and restric-
tion products were electrophoretically separated 
in 2% agarose gel and visualized with the use of ViТran 
system.
Homozygotes by CYP 2D6*4 (А1934A — *4*4) were 
identified by the presence of two fragments with the 
length of 77 and 344 b.p., and homozygotes by wild 
type (G1934G — *1*1) — by the presence of three 
fragments with the length of 77, 161 and 183 b.p. 
Heterozygotes (G1934A — *1*4) were presented 
by four fragments with the length of 77, 161, 183 and 
344 b.p. (Fig. 2).
344 b.p. —
183 b.p. —
161 b.p. —
77 b.p. —
Fig. 2. Electrophoretic analysis of restriction fragments of CYP 
2D6 gene in 2% agarose gel. CYP 2D6 *1*1– lines 4, 5, 6, 8, 10, 
11, 14, 15; 17; CYP2D6 *1*4 — lines 1, 2, 3, 7, 9, 13, 16; CYP 
2D6 *4*4 — line 12; М — molecular weight marker 
The data were analyzed with the use of Statistica 
6.0 program. For determination of significance of dif-
ferences between genotype frequencies in compared 
groups, standard x-square criterion (χ2) was used. 
Odds Ratio (OR) has been used for evaluation of rela-
tive risk of disease development for each genotype. 
In all types of analysis, values p<0.05 were considered 
significant.
RESULTS AND DISCUSSION
When we have compared group І of BC patients 
with the control group, significant difference between 
the frequencies of genotypes and alleles for *1*1 (ЕМ) 
and *4*4 (РM) of CYP 2D6 gene has been registered 
(Table 1).
In a separate analysis of distribution of genotypes 
and alleles by CYP 2D6 in hereditary tainted BC pa-
tients and control group (Tables 1 and 2), there has 
been registered higher increase of the risk of BC de-
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velopment in females from subgroup Іa with genotype 
*4*4, not only in comparison with control group but 
also in comparison with the whole group of BC patients 
(OR 3.59 and 2.77 respectively).
Table 1. Distribution of CYP 2D6 genotypes and alleles in groups І and ІІ
Gene 
polymor-
phism
Genet-
ypes, al-
leles
Group І 
n = 85
Control 
group
n = 637
χ2 OR CI
n % n %
CYP2D6*4 EM (*1*1) 45 52.94 417 65.46 5.1 0.59 0.38–0.94
IM (*1*4) 34 40.00 203 31.87 2.25 1.43 0.9–2.27
PM (*4*4) 6 7.06 17 2.67 4.69 2.77 1.06–7.23
p (*1) 0.73 0.81 6.81 0.62 0.43–0.89
q (*4) 0.27 0.19 1.62 1.12–2.34
Table 2. Polymorphism of CYP 2D6 gene in hereditary tainted patients 
Gene 
polymor-
phism
Geno-
types, al-
leles
Group Іa
n = 67
Control 
group
n = 637
χ2 OR CI
n % n %
CYP2D6*4 EM (*1*1) 33 49.25 417 65.46 6.91 0.51 0.31–0.85
IM (*1*4) 28 41.79 203 31.87 2.71 1.53 0.92–2.56
PM (*4*4) 6 8.96 17 2.67 7.58 3.59 1.36–9.44
p (*1) 0.7 0.81 9.71 0.54 0.36–0.8
q (*4) 0.3 0.19 1.86 1.25–2.77
This fact evidences on increased risk of BC de-
velopment in hereditary tainted patients compared 
to control group. The frequency of genotype *1*4 (IM) 
was found to be increased in the group of females 
with family history of cancer (41.79%). The presence 
of genotype *1*1 (ЕМ) may have a protective effect 
what is evidenced by OR value.
The comparison of the data obtained in hereditary 
untainted patients group (group Іb) and other groups 
in the study did not reveal significant differences in the 
frequencies of alleles and genotypes of CYP 2D6 gene 
what could be explained by a small number of patients 
in this group.
During the study of genotyping by CYP 2D6 gene 
we have revealed (Table 3) that distribution of fre-
quencies of alleles and genotypes of CYP 2D6 gene 
significantly differs from Mendel’s distribution. We did 
not find explanation for the meaning of non-Men-
del’s distribution of the frequences of CYP 2D6 gene 
and genotypes in the literature. By our opinion, the 
causes of such distribution could be: 1) age of muta-
tion: if the mutation appeared relatively recently, it has 
no time to be accumulated, so the dominant majority 
of individuals still have just one allele of defect gene 
(heterozygous status — *1*4), as it occurs in general 
population (control group); 2) influence on reproduc-
tive function — sex hormones (progesterone and 
estrogen) belong to endogenous substrates of CYP 
2D6 in human body, that’s why the decrease of en-
zyme activity disturbs their metabolism what affects 
the development of pregnancy; 3) early prenatal death 
of fetus with genotype *4*4 may lead to decreased 
accumulation of this genotype among population 
in total; 4) postnatal selectivity — increase of adap-
tive capabilities in individuals with certain genotype. 
Estimation of real cause of such distribution should 
be studied separately.
Table 3. Distribution of CYP 2D6 genotypes and alleles in the studied groups 
*1*1 (EM) *1*4 (IM) *4*4  (PM)
*1*4 + 
*4*4
Allele fre-
quency
n % n % n % n % p (*1)
q 
(*4)
Group І
n=85
45 52.94 34 40 6 7.06 40 47 0.73 0.27
Group І Group Іa
n=67
33 49.25 28 41.79 6 8.96 34 51 0.7 0.3
Group Іb
n=18
12 66.67 6 33.33 0 0 6 50 0.83 0.17
Control group
n=637
417 65.46 203 31.87 17 2.67 220 34 0.81 0.19
Our results have shown significant elevation of the 
frequency of heterozygotes *1*4 (IM) in BC patients 
and as a consequence, an increase of the number of in-
dividuals carrying at least one allele *4 (*1*4+*4*4). 
As far as homozygosity by allele *4 forms phenotype 
РМ [8], we have united homozygotes (РМ) and het-
erozygotes (IM) by allele *4 and have registered sig-
nificant increase of the frequency of allele *4 (47.06%) 
carriage compared to control group (34.54%) (OR 
(CI 95%): 1.68 (1.07–2.66); χ2=5.1).
The analysis of receptor status of BC patients did 
not reveal significant difference between the frequen-
cies of genotypes by CYP 2D6 for estrogen receptor-
positive (ER+) and estrogen-receptor-negative (ER–) 
tumors. However, there has been registered significant 
increase of the frequency of heterozygotes *1*4 and 
decrease of homozygotes *1*1 in patients with pro-
gesterone receptor positive (PR+) and progesterone 
receptor-negative (PR–) tumors in the group of he-
reditary tainted BC patients (Table 4).
Table 4. CYP2D6 polymorphism and receptor status 
Gene 
polymor-
phism
Geno-
types, al-
leles
Group 
Іa PR+
n = 37
Group 
Іa PR–
n = 30
р χ2 OR CI
n % n %
CYP2D6*4 EM (*1*1) 14 37.89 19 63.33 0.05 4.31 0.35 0.13-0.95
IM (*1*4) 20 54.05 8 26.67 0.02 5.11 3.24 1.15-9.11
PM (*4*4) 3 8.11 3 10 1 0.07 0.79 0.15-4.25
p (*1) 0.65 0.77 0.18 2.2 0.56 0.26-1.21
q (*4) 0.35 0.23 1.78 0.83-3.83
In conclusion, our study has revealed an increased 
risk of BC development in hereditary tainted patients 
compared to control group with genotype *4*4 (РМ) 
of CYP 2D6 gene. The frequency of genotype *1*4 (IM) 
has been found to be elevated in the group of women 
with family history of cancer (41.79%). The highest 
frequency of heterozygotes was found in hereditary 
tainted BC patients, while in BC patients without fam-
ily history of cancer it was found to be close to that 
in control group. Alsowe have revealed a significant 
difference in the frequency of genotypes *1*1 (ЕМ) 
and *1*4 (ІМ) in hereditary tainted BC patients with 
PR+ and PR–tumors.
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